Virios Therapeutics, Inc. - Common Stock (VIRI)

Competitors to Virios Therapeutics, Inc. - Common Stock (VIRI)

Aldeyra Therapeutics, Inc. 

Aldeyra focuses on its innovative therapies for ocular and systemic diseases and competes with Virios Therapeutics in the area of novel treatment approaches. Although both companies aim to address diseases with viral components, Aldeyra's established clinical programs and research footprint provide it with more credibility and scope in the marketplace.

Horizon Therapeutics plc

Horizon Therapeutics focuses on rare and autoimmune diseases, with a pipeline that occasionally intersects with viral-induced conditions. While their primary focus is not directly aligned with that of Virios Therapeutics, their larger operational scale and the ability to execute on a wide-ranging product pipeline represent a competitive advantage over Virios.

Moderna, Inc. 

Moderna is a leader in mRNA technology and has leveraged this for vaccine development against various viral infections, creating a significant market presence. While Virios Therapeutics targets specific viral-induced disorders, Moderna's extensive resources and established reputation give it a competitive advantage in the broader infectious disease market.

Sorrento Therapeutics, Inc.

Sorrento Therapeutics is engaged in developing a wide range of therapeutic candidates across various diseases, including those addressing viral infections. Their comprehensive approach and larger market presence give them an advantage over Virios Therapeutics, which is more specialized in its focus. Sorrento’s established partnerships and funding also bolster their competitive position.

XBiotech Inc. 

XBiotech focuses on developing therapies for infectious diseases and cancers, similar to Virios Therapeutics, which specializes in viral-induced diseases. Both companies are working on targeted treatments, but XBiotech's robust clinical pipeline and expertise in monoclonal antibodies provide them a competitive edge in terms of advanced therapeutic options.